Rznomics Inc.
KKRX:47683024,700.00
KRW
-400.00
(-1.59%)
ISIN
KR7476830005
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Seong-Wook Lee
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seongnam-si South Korea
- IPO Date
- Dec 18, 2025
- Website
- rznomics.com
- Similar Companies
- Business
- Rznomics Inc. is a South Korea-based clinical-stage biopharmaceutical company specializing in the discovery and development of RNA-based gene therapeutics for oncology indications and intractable genetic disorders. Founded in 2017 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, the company operates in the biotechnology sector, engineering precision RNA editing, trans-splicing, and circular RNA technologies to address unmet medical needs. Rznomics maintains corporate and research and development operations in South Korea as well as clinical and business development operations in the United States. The company's primary technology platforms and therapeutic product candidates include: the proprietary Trans-Splicing Ribozyme (TSR) platform, an RNA-replacement and editing technology designed to cleave target disease-associated RNA sequences and simultaneously trans-splice therapeutic RNA molecules without inducing permanent genomic DNA alterations; the scarless Circular RNA (circRNA) platform, utilizing an end-to-end self-targeting and splicing (STS) reaction driven by a group I intron ribozyme to generate highly stable circular RNA transcripts for sustained therapeutic protein expression and vaccine development; RZ-001 (taspitimagene advec), an adenoviral vector-mediated ribozyme gene therapy designed to target human telomerase reverse transcriptase (hTERT) RNA and induce selective cytotoxic herpes simplex virus thymidine kinase (HSV-tk) expression, in clinical development for hepatocellular carcinoma (HCC) and glioblastoma multiforme (GBM); RZ-004, an adeno-associated virus (AAV)-delivered gene therapy utilizing ribozyme technology to repair mutant rhodopsin transcripts for the treatment of autosomal dominant retinitis pigmentosa (adRP); RZ-003, a discovery-stage RNA-editing program targeting APOE4 transcripts for the treatment of Alzheimer's disease; and RZ-005, a discovery-stage therapeutic candidate targeting MECP2 for the treatment of Rett syndrome. In recent developments, Rznomics completed its initial public offering on the KOSDAQ market of the Korea Exchange under ticker 476830 in December 2025. In August 2026, the company expanded its United States footprint by joining Lilly Gateway Labs in San Diego, California, securing advanced laboratory infrastructure and strategic collaboration avenues with Eli Lilly and Company to accelerate its global RNA pipeline development. This followed a research collaboration and licensing agreement signed with Eli Lilly in May 2025 to co-develop novel RNA-editing therapies for rare hearing-loss disorders. In August 2024, Rznomics signed a multi-year master collaboration agreement with global contract development and manufacturing organization (CDMO) SK pharmteco to support analytical development, viral vector production, and commercial-scale manufacturing of its ribozyme-based gene therapies. Lead candidate RZ-001 has advanced into Phase 1b/2a clinical trials in both hepatocellular carcinoma and glioblastoma, having secured Regenerative Medicine Advanced Therapy (RMAT) designation, Fast Track designation, and Orphan Drug designation from the United States Food and Drug Administration (FDA), as well as the assignment of its International Nonproprietary Name, taspitimagene advec.